Christine J. Martin
Research Subjects
Christine J. Martin has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Barrie Wilkinson
Biotica Technology Limited, Chesterford Research Park, Essex CB10 1XL, U.K., Section of Structural Biology, Chester Beatty Laboratories, Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, U.K., and CompChem Solutions, St. John’s Innovation Centre, Cowley Road, Cambridge CB4 0WS, U.K.
1 shared publication- Chrisostomos Prodromou
Department of Biochemistry and Biomedicine, University of Sussex, Brighton BN1 9QG, UK
1 shared publication Iain R. Challis
Biotica Technology Limited, Chesterford Research Park, Essex CB10 1XL, U.K., Section of Structural Biology, Chester Beatty Laboratories, Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, U.K., and CompChem Solutions, St. John’s Innovation Centre, Cowley Road, Cambridge CB4 0WS, U.K.
1 shared publicationIsabelle Carletti
Biotica Technology Limited, Chesterford Research Park, Essex CB10 1XL, U.K., Section of Structural Biology, Chester Beatty Laboratories, Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, U.K., and CompChem Solutions, St. John’s Innovation Centre, Cowley Road, Cambridge CB4 0WS, U.K.
1 shared publication- Laurence H. Pearl
Genome Damage and Stability Centre, School of Life Sciences, University of Sussex, Falmer, Brighton BN1 9RQ, UK
1 shared publication Matthew Gregory
Biotica Technology Limited, Chesterford Research Park, Essex CB10 1XL, U.K., Section of Structural Biology, Chester Beatty Laboratories, Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, U.K., and CompChem Solutions, St. John’s Innovation Centre, Cowley Road, Cambridge CB4 0WS, U.K.
1 shared publication
Latest Publications
- 22 March 2008
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (9) , 2853-2857
Molecular Characterization of Macbecin as an Hsp90 Inhibitor
Macbecin compares favorably to geldanamycin as an Hsp90 inhibitor, being more soluble, stable, more potently inhibiting ATPase activity (IC50 = 2 µM) and binding with higher affinity (Kd = 0.24 µM). Structural studies reveal significant differences in their Hsp90 binding characteristics, and macbecin-induced tumor cell growth inhibition is accompanied by characteristic degradation of Hsp90 client proteins. Macbecin significantly reduced tumor growth rates (minimum T/C: 32%) in a DU145 murine xenograft. Macbecin thus represents an attractive lead for further optimization.
- 22 March 2008
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (9) , 2853-2857
Molecular Characterization of Macbecin as an Hsp90 Inhibitor
Macbecin compares favorably to geldanamycin as an Hsp90 inhibitor, being more soluble, stable, more potently inhibiting ATPase activity (IC50 = 2 µM) and binding with higher affinity (Kd = 0.24 µM). Structural studies reveal significant differences in their Hsp90 binding characteristics, and macbecin-induced tumor cell growth inhibition is accompanied by characteristic degradation of Hsp90 client proteins. Macbecin significantly reduced tumor growth rates (minimum T/C: 32%) in a DU145 murine xenograft. Macbecin thus represents an attractive lead for further optimization.